Biomarkers for Predicting Serious Cardiac Outcomes at 72 Hours in Patients Presenting Early after Chest Pain Onset with Symptoms of Acute Coronary Syndromes
- 1 January 2012
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (1) , 298-302
Abstract
BACKGROUND: Most outcome studies of patients presenting early to the emergency department with potential acute coronary syndromes have focused on either the index diagnosis of myocardial infarction (MI) or a composite end point at a later time frame (30 days or 1 year). We investigated the performance of 9 biomarkers for an early serious outcome. METHODS: Patients (n = 186) who presented to the emergency department within 6 h of chest pain onset had their presentation serum sample measured for the following analytes: creatine kinase, creatine kinase isoenzyme MB, enhanced AccuTnI troponin I (Beckman Coulter), high-sensitivity cardiac troponin T (hs-cTnT), ischemia-modified albumin, interleukin-6, investigation use only hs-cTnI (Beckman Coulter), N-terminal pro–B-type natriuretic peptide, and cardiac troponin I (Abbott AxSym). We followed patients until 72 h after presentation and determined whether they experienced the following serious cardiac outcomes: MI, heart failure, serious arrhythmia, refractory ischemic cardiac pain, or death. ROC curves were analyzed to determine the area under the ROC curve (AUC) and optimal cutoffs for the biomarkers. RESULTS: The AUCs for the hs-cTnI assay (0.86; 95% CI, 0.76–0.96), the AccuTnI assay (0.86; 95% CI, 0.78–0.95), and the hs-cTnT assay (0.82; 95% CI, 0.71–0.94) assays were significantly higher than those for the other 6 assays (AUC values ≤0.71 for the rest of the biomarkers, P < 0.05). The ROC curve–derived optimal cutoffs were ≥19 ng/L (diagnostic sensitivity, 80%; specificity, 88%), ≥0.018 μg/L (diagnostic sensitivity, 75%; specificity, 86%), and ≥32 ng/L (diagnostic sensitivity, 68%; specificity, 92%) for the hs-cTnI, AccuTnI, and hs-cTnT assays, respectively. CONCLUSIONS: The optimal cutoffs for predicting serious cardiac outcomes in this low-risk population are different from the published 99th percentiles. Larger studies are required to verify these findings.Keywords
Funding Information
- Abbott
- Beckman Coulter Foundation
- Roche
- Canadian Institutes of Health Research
This publication has 20 references indexed in Scilit:
- Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assays—An update from the Canadian society of clinical chemists (CSCC)Clinical Biochemistry, 2011
- High-Sensitivity Cardiac Troponin I Measurement for Risk Stratification in a Stable High-Risk PopulationClinical Chemistry, 2011
- Highly Sensitive Troponin Assays and the Cardiology Community: A Love/Hate Relationship?Clinical Chemistry, 2011
- Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General PopulationJAMA, 2010
- Association of Serial Measures of Cardiac Troponin T Using a Sensitive Assay With Incident Heart Failure and Cardiovascular Mortality in Older AdultsJAMA, 2010
- Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin IJACC, 2010
- Early Diagnosis of Myocardial Infarction with Sensitive Cardiac Troponin AssaysNew England Journal of Medicine, 2009
- Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial InfarctionNew England Journal of Medicine, 2009
- Universal Definition of Myocardial InfarctionJACC, 2007
- Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndromeCanadian Medical Association Journal, 2005